231 related articles for article (PubMed ID: 23000388)
21. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
22. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S;
Eur J Cancer; 2013 May; 49(8):1905-14. PubMed ID: 23490647
[TBL] [Abstract][Full Text] [Related]
23. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
24. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract][Full Text] [Related]
26. Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre.
Anfinan N; Sait K; Ghatage P; Nation J; Chu P
Arch Gynecol Obstet; 2011 Sep; 284(3):731-5. PubMed ID: 20963432
[TBL] [Abstract][Full Text] [Related]
27. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
[TBL] [Abstract][Full Text] [Related]
28. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors predicting recurrence in borderline ovarian tumors.
Wu TI; Lee CL; Wu MY; Hsueh S; Huang KG; Yeh CJ; Lai CH
Gynecol Oncol; 2009 Aug; 114(2):237-41. PubMed ID: 19481786
[TBL] [Abstract][Full Text] [Related]
30. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
31. Recurrence and prognostic factors in borderline ovarian tumors.
Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
[TBL] [Abstract][Full Text] [Related]
32. New Pointers for Surgical Staging of Borderline Ovarian Tumors.
Bendifallah S; Nikpayam M; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
Ann Surg Oncol; 2016 Feb; 23(2):443-9. PubMed ID: 26442919
[TBL] [Abstract][Full Text] [Related]
33. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
34. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors.
Ren J; Peng Z; Yang K
Gynecol Oncol; 2008 Aug; 110(2):162-7. PubMed ID: 18495223
[TBL] [Abstract][Full Text] [Related]
35. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
36. RAS Mutation in Mucinous Carcinoma of the Ovary.
Panyavaranant P; Teerapakpinyo C; Pohthipornthawat N; Oranratanaphan S; Shuangshoti S; Triratanachat S
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1127-1132. PubMed ID: 31030485
[TBL] [Abstract][Full Text] [Related]
37. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
[TBL] [Abstract][Full Text] [Related]
38. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
Djordjevic B; Malpica A
Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
[TBL] [Abstract][Full Text] [Related]
39. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change?
Chiesa AG; Deavers MT; Veras E; Silva EG; Gershenson D; Malpica A
Int J Gynecol Pathol; 2010 Mar; 29(2):108-12. PubMed ID: 20173495
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the KRAS gene in ovarian tumors.
Dobrzycka B; Terlikowski SJ; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(2):221-4. PubMed ID: 19995707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]